SynthesisOrphanet journal of rare diseases2026
Swallowing and feeding after disease-modifying treatment for spinal muscular atrophy: a systematic review of assessment modalities and outcomes.
Synthesis in Orphanet journal of rare diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Strengthening adaptive functioning and participation in the contemporary spinal muscular atrophy paradigm: clinical perspectives and future directions.World journal of pediatrics : WJP · 2026Review
- SMΝΔ7 mice show breathing and airflow defects with significant pathology of respiratory and oral tract tissues.Frontiers in cellular neuroscience · 2026Article
- Behavioral barriers in the management of spinal muscular atrophy: The role of procrastination, regret, and burnout.PloS one · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFeeding and swallowing deficits are reported across the spectrum of spinal muscular atrophy (SMA), with more profound symptoms associated with more severe disease. Patients treated with disease-modifying therapies (DMTs) demonstrate significantly improved life expectancy and motor function relative to untreated counterparts; however, limited data exist regarding the impact of DMTs on bulbar integrity, with evidence suggesting bulbar symptoms may persist, even when motor function has improved. This systematic literature review was conducted to identify assessments used to evaluate swallowing in patients with SMA treated with DMTs, and to describe the impact of DMTs on swallowing and feeding outcomes. Embase, MEDLINE, and Cochrane central were searched from May 2021 to February 2024 for studies reporting swallowing and feeding outcomes in patients treated with nusinersen, onasemnogene abeparvovec, and risdiplam.
resultsSeventy-one studies were included. The majority of studies (99%, n = 71) reported functional swallow outcomes, such as oral intake status or patient-reported outcomes, and only 19% reported results from clinician-administered assessments. Results from imaging assessments were rarely reported (5%, n = 4 studies). Only 68% of studies reported results from both pre- and post-treatment assessments. Patients who received DMT prior to symptom onset were found to have good functional outcomes, with 84–100% receiving full oral nutrition. Treatment after symptom onset yielded variable results, with trends suggesting that treatment outcomes are influenced by the level of impairment at baseline and the type of swallowing assessment used. The ability to maintain pre-treatment swallow integrity was variable across studies.
conclusionAlthough evidence suggests that DMTs can preserve or improve bulbar function in SMA, swallowing and feeding are not regularly or homogeneously assessed across the literature, making comparisons across studies difficult. Standardised and validated assessments of swallowing physiology and swallowing function are needed to understand what factors may influence bulbar outcomes with DMTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.